• Acquisition of the PRI-002, PRI-003, and PRI-004 IP portfolio from Forschungszentrum Jülich
  • Successful completion of the first-in-human phase I SAD clinical trial for PRI-002
  • Start of the Phase I MAD clinical trial for PRI-002 in December 2018
  • Founding of Priavoid
  • Initiation of series A financing
  • Basic Research at Forschungszentrum Jülich
  • Research funding by Forschungszentrum Jülich, Helmholtz Gesellschaft, HHU Düsseldorf, VW Stiftung

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!



To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice